On the evening of November 6, the Shanghai Stock Exchange gave the green light to Shenzhen CoreMed Technology Co., Ltd.'s Initial Public Offering (IPO) application, paving the way for its listing on the STAR Market. This milestone marks CoreMed as the inaugural innovative medical device company to be approved under the fifth listing criterion of the STAR Market since its relaunch. Established in 2016, CoreMed has carved out a niche in the research, development, and manufacturing of cutting-edge medical devices, with a particular focus on artificial hearts. The company has successfully navigated multiple funding rounds, attracting prominent investors such as Hillhouse Capital.
